Rajaratnam Misses Court After Surgery, No Jury Deliberations Today

May 3 2011 | 4:08am ET

Medical matters dominated the sixth day of deliberations at the Raj Rajaratnam insider-trading trial, which ended as the five previous days ended: without a verdict.

Rajaratnam himself wasn't in the courtroom: The Galleon Group chief was excused by U.S. District Judge Richard Holwell, having had emergency surgery to treat a bacterial infection of his foot on Sunday.

"It is hoped that he will be recovered sufficiently to return to the courthouse this week," Rajaratnam's lawyer, John Dowd, said in a statement. "The court has approved this absence."

Holwell echoed that statement before dismissing the jury, telling them that Rajaratnam "couldn't be here and I've excused him for a good reason."

None of them will be there today: A juror's medical procedure has pre-empted the deliberations, which will enter their seventh day tomorrow. The delay came after the jurors sent Holwell a note yesterday—their first communication with the court since Wednesday. The note, dealing with the medical issue, was not released, but Holwell's letter to the jury was.

"No juror should feel any time pressure whatsoever," he wrote. "The jury will have all the time it needs to reach its verdict."

As for Rajaratnam, his spokesman, Jim McCarthy, said he understood that Rajaratnam would not have to be in court tomorrow. He added that he believed a verdict could be handed down whether or not Rajaratnam is present.

If Rajaratnam is convicted, he faces decades in prison.


In Depth

Steinbrugge: Will Hedge Funds Help or Hurt During the Next Market Correction?

Sep 7 2016 | 11:55pm ET

Most investors have become accustomed to quick rebounds when markets correct, but...

Lifestyle

Quattrex Sports AG Debuts Soccer-Focused UCITS Fund

Sep 9 2016 | 9:54pm ET

Innovative alternative investment company Quattrex Sports has unveiled a new UCITS...

Guest Contributor

Malik: The Ever-Changing Middle Market and The Entering Class of 2016

Sep 2 2016 | 5:01pm ET

Deal sourcing and origination is only going to get more competitive given current...